Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1,500 | $6,200 | $500 | $7,143 |
| % Growth | -75.8% | 1,140% | -93% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,500 | $6,200 | $500 | $7,143 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $22,764 | $23,578 | $39,052 | $64,535 |
| G&A Expenses | $5,717 | $7,010 | $15,531 | $29,972 |
| SG&A Expenses | $5,717 | $7,010 | $15,531 | $29,972 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $7 | $112 | $0 |
| Operating Expenses | $28,481 | $30,588 | $54,583 | $94,507 |
| Operating Income | -$26,981 | -$24,866 | -$51,692 | -$87,364 |
| % Margin | -1,798.7% | -401.1% | -10,338.4% | -1,223.1% |
| Other Income/Exp. Net | $2,010 | $15,161 | -$10,113 | -$25,113 |
| Pre-Tax Income | -$24,971 | -$9,705 | -$7,722 | -$112,477 |
| Tax Expense | $2 | -$127 | $897 | $13,615 |
| Net Income | -$24,973 | -$9,578 | -$8,619 | -$126,092 |
| % Margin | -1,664.9% | -154.5% | -1,723.8% | -1,765.3% |
| EPS | -0.81 | -0.83 | -1.5 | -26.92 |
| % Growth | 2.4% | 44.7% | 94.4% | – |
| EPS Diluted | -0.81 | -0.83 | -1.5 | -26.92 |
| Weighted Avg Shares Out | 30,828 | 11,504 | 5,760 | 4,685 |
| Weighted Avg Shares Out Dil | 30,828 | 11,504 | 5,760 | 4,685 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $32 | $387 | $1,351 |
| Interest Expense | $0 | $4 | $2,659 | $4,280 |
| Depreciation & Amortization | -$1,953 | $517 | -$1,892 | $19,192 |
| EBITDA | -$26,981 | -$24,349 | $2,391 | -$87,364 |
| % Margin | -1,798.7% | -392.7% | 478.2% | -1,223.1% |